Abstract
The literature is replete with reports of the paradoxical role of Notch signaling in human cancer. Notch appears to act as both an oncogene and a tumor suppressor gene depending on the cellular context. This review focuses on the nascent knowledge of Notch signaling in ovarian cancer. Despite advances in chemotherapy and radical surgery, ovarian cancer remains the most deadly gynecologic malignancy. Therapeutic improvements are necessary to enhance outcomes of patients with ovarian cancer. I will review the evidence for Notch activation in ovarian cancer and potential strategies for Notch inactivation as targeted treatment of ovarian cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
